|
|
|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
B
|
|
INDICATIONS:
|
|
Anesthesia, local |
|
Anesthesia, topical |
| |
|
|
SIDE EFFECTS:
|
|
Allergic contact dermatitis |
|
angioedema |
|
burning, stinging, swelling, or tenderness not present before therapy |
|
Urethritis |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
Hemorrhoids, bleeding-for rectal use |
|
Local infection at area of treatment |
|
Sensitivity to the local anesthetic being considered for use and/or chemically related anesthetics or other compounds |
|
Traumatized mucosa, severe |
|
|
ADULT DOSE:
|
|
Anesthetic, mucosal-local-Endoscopic procedures: Topical, up to 20 metered sprays (200 mg [base]) as a 10% (base) solution, sprayed onto the oropharyngeal or tracheal mucosa. |
|
MAXIMUM ADULT DOSE:
|
|
|
|
PEDIATRIC DOSE:
|
|
Anesthetic, mucosal-local-Infants and children up to 3 years of age- Use is not recommended; a less concentrated solution should be used instead.
Children 3 to 12 years of age- Larynx or trachea-Topical, up to 1.5 mg (base) per kg of body weight.
Other mucosa-Topical, up to 3 mg (base) per kg of body weight. |
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
|
|
|
|
|
|